InMode Ltd. (NASDAQ:INMD) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• InMode Ltd. has received a consensus rating of "Hold" from eight research firms, with seven analysts recommending a hold and one a buy.
• The company's shares recently opened at $14.95, with an average price target of $18.04 from analysts and a market capitalization of approximately $944.99 million.
• InMode reported earnings of $0.47 per share for the last quarter, which was below analyst expectations of $0.50, despite a year-over-year revenue increase of 10.6%.

Shares of InMode Ltd. (NASDAQ:INMD - Get Free Report) have been assigned a consensus rating of "Hold" from the eight research firms that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $18.0417.

A number of analysts have commented on the company. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research report on Wednesday, July 30th. Canaccord Genuity Group reiterated a "hold" rating and set a $15.00 target price on shares of InMode in a research report on Friday, July 11th. Finally, Barclays decreased their target price on InMode from $24.00 to $21.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th.

InMode Price Performance

Shares of INMD stock opened at $14.95 on Thursday. The business's fifty day moving average price is $14.54 and its 200 day moving average price is $15.05. InMode has a 1-year low of $13.14 and a 1-year high of $19.85. The firm has a market capitalization of $944.99 million, a PE ratio of 6.05 and a beta of 2.00.

InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The healthcare company reported $0.47 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.03). The business had revenue of $95.60 million for the quarter, compared to analyst estimates of $98.45 million. InMode had a return on equity of 18.38% and a net margin of 44.50%.The company's revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.34 EPS. Equities research analysts expect that InMode will post 1.75 earnings per share for the current fiscal year.

Institutional Trading of InMode

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC lifted its position in shares of InMode by 63.1% in the second quarter. Parallel Advisors LLC now owns 1,973 shares of the healthcare company's stock valued at $28,000 after acquiring an additional 763 shares in the last quarter. American Century Companies Inc. lifted its position in shares of InMode by 6.1% in the first quarter. American Century Companies Inc. now owns 18,994 shares of the healthcare company's stock valued at $337,000 after acquiring an additional 1,087 shares in the last quarter. CWM LLC lifted its position in shares of InMode by 106.4% in the first quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock valued at $42,000 after acquiring an additional 1,221 shares in the last quarter. Aviva PLC lifted its position in shares of InMode by 3.9% in the second quarter. Aviva PLC now owns 33,264 shares of the healthcare company's stock valued at $480,000 after acquiring an additional 1,263 shares in the last quarter. Finally, Cary Street Partners Financial LLC lifted its position in shares of InMode by 1.0% in the first quarter. Cary Street Partners Financial LLC now owns 133,867 shares of the healthcare company's stock valued at $2,375,000 after acquiring an additional 1,315 shares in the last quarter. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.